Catalyst Biosciences (CBIO) Major Shareholder Sells $1,619,471.07 in Stock

Catalyst Biosciences (NASDAQ:CBIO) major shareholder James E. Flynn sold 52,461 shares of the stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $30.87, for a total value of $1,619,471.07. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

CBIO traded down $2.20 during mid-day trading on Monday, reaching $23.60. The stock had a trading volume of 260,269 shares, compared to its average volume of 437,320. The firm has a market capitalization of $306.86, a price-to-earnings ratio of -3.17 and a beta of 2.51. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $37.00.

How to Become a New Pot Stock Millionaire

Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.41) by $0.45. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.23 million. Catalyst Biosciences had a negative return on equity of 86.40% and a negative net margin of 2,117.98%. equities analysts forecast that Catalyst Biosciences will post -4.16 earnings per share for the current fiscal year.

CBIO has been the topic of a number of research analyst reports. B. Riley set a $49.00 price target on Catalyst Biosciences and gave the stock a “buy” rating in a research report on Friday, February 9th. Chardan Capital increased their price objective on Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 9th. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Tuesday, January 2nd. BidaskClub lowered Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, ValuEngine upgraded Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $37.50.

Hedge funds have recently bought and sold shares of the company. Ardsley Advisory Partners acquired a new position in shares of Catalyst Biosciences in the 4th quarter valued at $205,000. Bank of New York Mellon Corp acquired a new position in shares of Catalyst Biosciences in the 2nd quarter valued at $107,000. Geode Capital Management LLC acquired a new position in shares of Catalyst Biosciences in the 4th quarter valued at $379,000. Raymond James & Associates acquired a new position in shares of Catalyst Biosciences in the 4th quarter valued at $585,000. Finally, Vanguard Group Inc. lifted its stake in shares of Catalyst Biosciences by 294.1% in the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 32,621 shares during the period. 24.41% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Catalyst Biosciences (CBIO) Major Shareholder Sells $1,619,471.07 in Stock” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/2018/04/02/catalyst-biosciences-inc-cbio-major-shareholder-james-e-flynn-sells-52461-shares/2007804.html.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.